Emerging classes of armed antibody therapeutics against cancer

Facile and Stabile Linkages through Tyrosine: Bioconjugation Strategies with the Tyrosine-Click Reaction

(2013) Hitoshi Ban et al.   BIOCONJUGATE CHEMISTRY

A Potent Anti-CD70 Antibody–Drug Conjugate Combining a Dimeric Pyrrolobenzodiazepine Drug with Site-Specific Conjugation Technology

(2013) Scott C. Jeffrey et al.   BIOCONJUGATE CHEMISTRY

SGN-CD33A: a novel CD33-targeting antibody-drug conjugate using a pyrrolobenzodiazepine dimer is active in models of drug-resistant AML

(2013) M. S. Kung Sutherland et al.   BLOOD

Cytokine release syndrome after blinatumomab treatment related to abnormal macrophage activation and ameliorated with cytokine-directed therapy

(2013) D. T. Teachey et al.   BLOOD

The antibody-based targeted delivery of TNF in combination with doxorubicin eradicates sarcomas in mice and confers protective immunity

(2013) T Hemmerle et al.   BRITISH JOURNAL OF CANCER

Location Matters: Site of Conjugation Modulates Stability and Pharmacokinetics of Antibody Drug Conjugates

(2013) Pavel Strop et al.   CHEMISTRY & BIOLOGY

Phase II Study of Lutetium-177-Labeled Anti-Prostate-Specific Membrane Antigen Monoclonal Antibody J591 for Metastatic Castration-Resistant Prostate Cancer

(2013) S. T. Tagawa et al.   CLINICAL CANCER RESEARCH

Two-in-One antibodies with dual action Fabs

(2013) Charles Eigenbrot et al.   CURRENT OPINION IN CHEMICAL BIOLOGY

Targeting T cells to tumor cells using bispecific antibodies

(2013) Stanley R Frankel et al.   CURRENT OPINION IN CHEMICAL BIOLOGY

Tumor targeting of the IL-15 superagonist RLI by an anti-GD2 antibody strongly enhances its antitumor potency

(2013) Marie Vincent et al.   INTERNATIONAL JOURNAL OF CANCER

The antibody-based targeted delivery of interleukin-4 and 12 to the tumor neovasculature eradicates tumors in three mouse models of cancer

(2013) Teresa Hemmerle et al.   INTERNATIONAL JOURNAL OF CANCER

Treatment of Triple-Negative Breast Cancer Using Anti-EGFR-Directed Radioimmunotherapy Combined with Radiosensitizing Chemotherapy and PARP Inhibitor

(2013) F. Al-Ejeh et al.   JOURNAL OF NUCLEAR MEDICINE

Immunotherapy with FBTA05 (Bi20), a trifunctional bispecific anti-CD3 x anti-CD20 antibody and donor lymphocyte infusion (DLI) in relapsed or refractory B-cell lymphoma after allogeneic stem cell transplantation: study protocol of an investigator-driven, open-label, non-randomized, uncontrolled, dose-escalating Phase I/II-trial

(2013) Raymund Buhmann et al.   Journal of Translational Medicine

Rescue of Impaired NK Cell Activity in Hodgkin Lymphoma With Bispecific Antibodies In Vitro and in Patients

(2013) Katrin S. Reiners et al.   MOLECULAR THERAPY

Bispecific antibodies with natural architecture produced by co-culture of bacteria expressing two distinct half-antibodies

(2013) Christoph Spiess et al.   NATURE BIOTECHNOLOGY

Maturing antibody–drug conjugate pipeline hits 30

(2013) Asher Mullard   NATURE REVIEWS DRUG DISCOVERY

Nivolumab plus Ipilimumab in Advanced Melanoma

(2013) Jedd D. Wolchok et al.   NEW ENGLAND JOURNAL OF MEDICINE

Preclinical evaluation of NETA-based bifunctional ligand for radioimmunotherapy applications using 212Bi and 213Bi: Radiolabeling, serum stability, and biodistribution and tumor uptake studies

(2013) Chi Soo Kang et al.   NUCLEAR MEDICINE AND BIOLOGY

Efficient generation of stable bispecific IgG1 by controlled Fab-arm exchange

(2013) A. F. Labrijn et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Antibody-Based Delivery of Interleukin-2 to Neovasculature Has Potent Activity Against Acute Myeloid Leukemia

(2013) K. L. Gutbrodt et al.   Science Translational Medicine

Antibody–cytokine fusion proteins

(2012) Roland E. Kontermann   ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS

Synthesis and Preclinical Evaluation of Bifunctional Ligands for Improved Chelation Chemistry of 90Y and 177Lu for Targeted Radioimmunotherapy

(2012) Chi Soo Kang et al.   BIOCONJUGATE CHEMISTRY

Dual-targeting immunotherapy of lymphoma: potent cytotoxicity of anti-CD20/CD74 bispecific antibodies in mantle cell and other lymphomas

(2012) P. Gupta et al.   BLOOD

Long-term follow-up of hematologic relapse-free survival in a phase 2 study of blinatumomab in patients with MRD in B-lineage ALL

(2012) M. S. Topp et al.   BLOOD

Fractionated radioimmunotherapy with90Y-clivatuzumab tetraxetan and low-dose gemcitabine is active in advanced pancreatic cancer

(2012) Allyson J. Ocean et al.   CANCER

Dual Targeting of EGFR and HER3 with MEHD7945A Overcomes Acquired Resistance to EGFR Inhibitors and Radiation

(2012) S. Huang et al.   CANCER RESEARCH

Paclitaxel Enhances Therapeutic Efficacy of the F8-IL2 Immunocytokine to EDA-Fibronectin-Positive Metastatic Human Melanoma Xenografts

(2012) M. Moschetta et al.   CANCER RESEARCH

Fucose-specific conjugation of hydrazide derivatives to a vascular-targeting monoclonal antibody in IgG format

(2012) Kathrin Zuberbühler et al.   CHEMICAL COMMUNICATIONS

Radioimmunotherapy of Fibroblast Activation Protein Positive Tumors by Rapidly Internalizing Antibodies

(2012) E. Fischer et al.   CLINICAL CANCER RESEARCH

The Antibody-Based Delivery of Interleukin-12 to the Tumor Neovasculature Eradicates Murine Models of Cancer in Combination with Paclitaxel

(2012) N. Pasche et al.   CLINICAL CANCER RESEARCH

Immunocytokines: a novel class of potent armed antibodies

(2012) Nadine Pasche et al.   DRUG DISCOVERY TODAY

A phase I dose-escalation study of the immunocytokine EMD 521873 (Selectikine) in patients with advanced solid tumours

(2012) Silke Gillessen et al.   EUROPEAN JOURNAL OF CANCER

Phase I/II study of the tumour-targeting human monoclonal antibody–cytokine fusion protein L19-TNF in patients with advanced solid tumours

(2012) G. Spitaleri et al.   JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY

Phase I Multidose-Escalation Study of the Anti-CD19 Maytansinoid Immunoconjugate SAR3419 Administered by Intravenous Infusion Every 3 Weeks to Patients With Relapsed/Refractory B-Cell Lymphoma

(2012) Anas Younes et al.   JOURNAL OF CLINICAL ONCOLOGY

Brentuximab Vedotin (SGN-35) in Patients With Relapsed or Refractory Systemic Anaplastic Large-Cell Lymphoma: Results of a Phase II Study

(2012) Barbara Pro et al.   JOURNAL OF CLINICAL ONCOLOGY

Results of a Pivotal Phase II Study of Brentuximab Vedotin for Patients With Relapsed or Refractory Hodgkin's Lymphoma

(2012) Anas Younes et al.   JOURNAL OF CLINICAL ONCOLOGY

The Immunocytokine L19–IL2 Eradicates Cancer When Used in Combination with CTLA-4 Blockade or with L19-TNF

(2012) Kathrin Schwager et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

Radioimmunotherapy with Radretumab in Patients with Relapsed Hematologic Malignancies

(2012) P. A. Erba et al.   JOURNAL OF NUCLEAR MEDICINE

Isolated limb perfusion with the tumor-targeting human monoclonal antibody-cytokine fusion protein L19-TNF plus melphalan and mild hyperthermia in patients with locally advanced extremity melanoma

(2012) Francesco Papadia et al.   JOURNAL OF SURGICAL ONCOLOGY

Site-Specific Traceless Coupling of Potent Cytotoxic Drugs to Recombinant Antibodies for Pharmacodelivery

(2012) Giulio Casi et al.   JOURNAL OF THE AMERICAN CHEMICAL SOCIETY

The discovery and development of brentuximab vedotin for use in relapsed Hodgkin lymphoma and systemic anaplastic large cell lymphoma

(2012) Peter D Senter et al.   NATURE BIOTECHNOLOGY

Conjugation site modulates the in vivo stability and therapeutic activity of antibody-drug conjugates

(2012) Ben-Quan Shen et al.   NATURE BIOTECHNOLOGY

Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer

(2012) Sunil Verma et al.   NEW ENGLAND JOURNAL OF MEDICINE

Preclinical evaluation of 227Th-labeled and 177Lu-labeled trastuzumab in mice with HER-2-positive ovarian cancer xenografts

(2012) Nasir Abbas et al.   NUCLEAR MEDICINE COMMUNICATIONS

Synthesis of site-specific antibody-drug conjugates using unnatural amino acids

(2012) J. Y. Axup et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Spacer length shapes drug release and therapeutic efficacy of traceless disulfide-linked ADCs targeting the tumor neovasculature

(2012) Martina Steiner et al.   Chemical Science

A Traceless Vascular-Targeting Antibody-Drug Conjugate for Cancer Therapy

(2011) Gonçalo J. L. Bernardes et al.   ANGEWANDTE CHEMIE-INTERNATIONAL EDITION

Application of dual affinity retargeting molecules to achieve optimal redirected T-cell killing of B-cell lymphoma

(2011) P. A. Moore et al.   BLOOD

Historical perspectives on tumor necrosis factor and its superfamily: 25 years later, a golden journey

(2011) B. B. Aggarwal et al.   BLOOD

A chemically modified antibody mediates complete eradication of tumours by selective disruption of tumour blood vessels

(2011) A Palumbo et al.   BRITISH JOURNAL OF CANCER

A Two-in-One Antibody against HER3 and EGFR Has Superior Inhibitory Activity Compared with Monospecific Antibodies

(2011) Gabriele Schaefer et al.   CANCER CELL

A Dose-Escalation and Signal-Generating Study of the Immunocytokine L19-IL2 in Combination with Dacarbazine for the Therapy of Patients with Metastatic Melanoma

(2011) T. K. Eigentler et al.   CLINICAL CANCER RESEARCH

A Phase 1 Study of AS1409, a Novel Antibody-Cytokine Fusion Protein, in Patients with Malignant Melanoma or Renal Cell Carcinoma

(2011) S. M. Rudman et al.   CLINICAL CANCER RESEARCH

A Low-Toxicity IL-2-Based Immunocytokine Retains Antitumor Activity Despite Its High Degree of IL-2 Receptor Selectivity

(2011) S. D. Gillies et al.   CLINICAL CANCER RESEARCH

Antibody-based targeting of interferon-alpha to the tumor neovasculature: a critical evaluation

(2011) Katharina Frey et al.   Integrative Biology

Humoral response to catumaxomab correlates with clinical outcome: Results of the pivotal phase II/III study in patients with malignant ascites

(2011) Marion G. Ott et al.   INTERNATIONAL JOURNAL OF CANCER

A biparatopic anti-EGFR nanobody efficiently inhibits solid tumour growth

(2011) Rob C. Roovers et al.   INTERNATIONAL JOURNAL OF CANCER

Cloning and characterization of novel tumor-targeting immunocytokines based on murine IL7

(2011) Nadine Pasche et al.   JOURNAL OF BIOTECHNOLOGY

Targeted Therapy With the T-Cell–Engaging Antibody Blinatumomab of Chemotherapy-Refractory Minimal Residual Disease in B-Lineage Acute Lymphoblastic Leukemia Patients Results in High Response Rate and Prolonged Leukemia-Free Survival

(2011) Max S. Topp et al.   JOURNAL OF CLINICAL ONCOLOGY

Antitumor Effects of a Human Dimeric Antibody Fragment 131I-AFRA-DFM5.3 in a Mouse Model for Ovarian Cancer

(2011) A. Zacchetti et al.   JOURNAL OF NUCLEAR MEDICINE

A phase I study evaluating ibritumomab tiuxetan (Zevalin®) in combination with bortezomib (Velcade®) in relapsed/refractory mantle cell and low grade B-cell non-Hodgkin lymphoma

(2011) Anne W. Beaven et al.   LEUKEMIA & LYMPHOMA

Immunoglobulin domain crossover as a generic approach for the production of bispecific IgG antibodies

(2011) W. Schaefer et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Experimental α-particle radioimmunotherapy of breast cancer using 227Th-labeled p-benzyl-DOTA-trastuzumab

(2011) Nasir Abbas et al.   EJNMMI Research

Site-Specific and Stoichiometric Modification of Antibodies by Bacterial Transglutaminase

(2010) Simone Jeger et al.   ANGEWANDTE CHEMIE-INTERNATIONAL EDITION

Combination of temozolomide with immunocytokine F16–IL2 for the treatment of glioblastoma

(2010) M Pedretti et al.   BRITISH JOURNAL OF CANCER

Targeting pancreatic and ovarian carcinomas using the auristatin-based anti-CD70 antibody–drug conjugate SGN-75

(2010) M C Ryan et al.   BRITISH JOURNAL OF CANCER

Pharmacokinetics, immunogenicity and bioactivity of the therapeutic antibody catumaxomab intraperitoneally administered to cancer patients

(2010) Peter Ruf et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Pretargeted radioimmunotherapy in rapidly progressing, metastatic, medullary thyroid cancer

(2010) Françoise Kraeber-Bodéré et al.   CANCER

The tumour-targeting human L19-IL2 immunocytokine: Preclinical safety studies, phase I clinical trial in patients with solid tumours and expansion into patients with advanced renal cell carcinoma

(2010) Manfred Johannsen et al.   EUROPEAN JOURNAL OF CANCER

Targeted alpha-radionuclide therapy of functionally critically located gliomas with 213Bi-DOTA-[Thi8,Met(O2)11]-substance P: a pilot trial

(2010) D. Cordier et al.   EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: Results of a prospective randomized phase II/III trial

(2010) Markus M. Heiss et al.   INTERNATIONAL JOURNAL OF CANCER

Safety, Pharmacokinetics, and Preliminary Clinical Activity of Inotuzumab Ozogamicin, a Novel Immunoconjugate for the Treatment of B-Cell Non-Hodgkin's Lymphoma: Results of a Phase I Study

(2010) Anjali Advani et al.   JOURNAL OF CLINICAL ONCOLOGY

Antitumor Activity of Hu14.18-IL2 in Patients With Relapsed/Refractory Neuroblastoma: A Children's Oncology Group (COG) Phase II Study

(2010) Suzanne Shusterman et al.   JOURNAL OF CLINICAL ONCOLOGY

Identification of Patients With Acute Myeloblastic Leukemia Who Benefit From the Addition of Gemtuzumab Ozogamicin: Results of the MRC AML15 Trial

(2010) Alan K. Burnett et al.   JOURNAL OF CLINICAL ONCOLOGY

Effector Cell Recruitment with Novel Fv-based Dual-affinity Re-targeting Protein Leads to Potent Tumor Cytolysis and in Vivo B-cell Depletion

(2010) Syd Johnson et al.   JOURNAL OF MOLECULAR BIOLOGY

The Immunocytokine F8-IL2 Improves the Therapeutic Performance of Sunitinib in a Mouse Model of Renal Cell Carcinoma

(2010) Katharina Frey et al.   JOURNAL OF UROLOGY

Biopharmaceutical benchmarks 2010

(2010) Gary Walsh   NATURE BIOTECHNOLOGY

Antibody−Drug Conjugates: Linking Cytotoxic Payloads to Monoclonal Antibodies

(2009) Laurent Ducry et al.   BIOCONJUGATE CHEMISTRY

Expression of the oncofetal ED-B-containing fibronectin isoform in hematologic tumors enables ED-B-targeted 131I-L19SIP radioimmunotherapy in Hodgkin lymphoma patients

(2009) S. Sauer et al.   BLOOD

A re-examination of radioimmunotherapy in the treatment of non-Hodgkin lymphoma: prospects for dual-targeted antibody/radioantibody therapy

(2009) R. M. Sharkey et al.   BLOOD

Immunoglobulin G4: an odd antibody

(2009) R. C. Aalberse et al.   CLINICAL AND EXPERIMENTAL ALLERGY

Radiofrequency Ablation Combined with KS-IL2 Immunocytokine (EMD 273066) Results in an Enhanced Antitumor Effect against Murine Colon Adenocarcinoma

(2009) E. E. Johnson et al.   CLINICAL CANCER RESEARCH

A Phase I Trial of Radioimmunotherapy with 131I-A5B7 Anti-CEA Antibody in Combination with Combretastatin-A4-Phosphate in Advanced Gastrointestinal Carcinomas

(2009) T. Meyer et al.   CLINICAL CANCER RESEARCH

ErbB receptors and signaling pathways in cancer

(2009) Nancy E Hynes et al.   CURRENT OPINION IN CELL BIOLOGY

Potent antibody drug conjugates for cancer therapy

(2009) Peter D Senter   CURRENT OPINION IN CHEMICAL BIOLOGY

124I-L19-SIP for immuno-PET imaging of tumour vasculature and guidance of 131I-L19-SIP radioimmunotherapy

(2009) Bernard M. Tijink et al.   EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

Therapy-induced antitumor vaccination in neuroblastomas by the combined targeting of IL-2 and TNFα

(2009) Enrica Balza et al.   INTERNATIONAL JOURNAL OF CANCER

Treatment of Malignant Pleural Effusion With the Trifunctional Antibody Catumaxomab (Removab) (Anti-EpCAM×Anti-CD3)

(2009) Martin Sebastian et al.   JOURNAL OF IMMUNOTHERAPY

Pretargeted Versus Directly Targeted Radioimmunotherapy Combined with Anti-CD20 Antibody Consolidation Therapy of Non-Hodgkin Lymphoma

(2009) R. M. Sharkey et al.   JOURNAL OF NUCLEAR MEDICINE

Intraperitoneal  -Particle Radioimmunotherapy of Ovarian Cancer Patients: Pharmacokinetics and Dosimetry of 211At-MX35 F(ab')2--A Phase I Study

(2009) H. Andersson et al.   JOURNAL OF NUCLEAR MEDICINE

Phase I/II open-label study of the biologic effects of the interleukin-2 immunocytokine EMD 273063 (hu14.18-IL2) in patients with metastatic malignant melanoma

(2009) Antoni Ribas et al.   Journal of Translational Medicine

A modeling analysis of the effects of molecular size and binding affinity on tumor targeting

(2009) M. M. Schmidt et al.   MOLECULAR CANCER THERAPEUTICS

High antitumor activity of RLI, an interleukin-15 (IL-15)-IL-15 receptor   fusion protein, in metastatic melanoma and colorectal cancer

(2009) A. Bessard et al.   MOLECULAR CANCER THERAPEUTICS

Variants of the Antibody Herceptin That Interact with HER2 and VEGF at the Antigen Binding Site

(2009) J. Bostrom et al.   SCIENCE

Alpha-particles for targeted therapy

(2008) George Sgouros   ADVANCED DRUG DELIVERY REVIEWS

Rituximab blocks binding of radiolabeled anti-CD20 antibodies (Ab) but not radiolabeled anti-CD45 Ab

(2008) A. K. Gopal et al.   BLOOD

Complete eradication of human B-cell lymphoma xenografts using rituximab in combination with the immunocytokine L19-IL2

(2008) C. Schliemann et al.   BLOOD

Immunotherapy of recurrent B-cell malignancies after allo-SCT with Bi20 (FBTA05), a trifunctional anti-CD3 × anti-CD20 antibody and donor lymphocyte infusion

(2008) R Buhmann et al.   BONE MARROW TRANSPLANTATION

Therapeutic Window of MuS110, a Single-Chain Antibody Construct Bispecific for Murine EpCAM and Murine CD3

(2008) M. Amann et al.   CANCER RESEARCH

Targeting HER2-Positive Breast Cancer with Trastuzumab-DM1, an Antibody-Cytotoxic Drug Conjugate

(2008) G. D. Lewis Phillips et al.   CANCER RESEARCH

The Targeted Immunocytokine L19-IL2 Efficiently Inhibits the Growth of Orthotopic Pancreatic Cancer

(2008) K. Wagner et al.   CLINICAL CANCER RESEARCH

Antibody-Mediated Delivery of Interleukin-2 to the Stroma of Breast Cancer Strongly Enhances the Potency of Chemotherapy

(2008) J. Marlind et al.   CLINICAL CANCER RESEARCH

Phase III Trial of Consolidation Therapy With Yttrium-90–Ibritumomab Tiuxetan Compared With No Additional Therapy After First Remission in Advanced Follicular Lymphoma

(2008) Franck Morschhauser et al.   JOURNAL OF CLINICAL ONCOLOGY

Anti-CD30 diabody-drug conjugates with potent antitumor activity

(2008) K. M. Kim et al.   MOLECULAR CANCER THERAPEUTICS

Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index

(2008) Jagath R Junutula et al.   NATURE BIOTECHNOLOGY

An engineered selenocysteine defines a unique class of antibody derivatives

(2008) T. Hofer et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Tumor Regression in Cancer Patients by Very Low Doses of a T Cell-Engaging Antibody

(2008) R. Bargou et al.   SCIENCE

Site-specific modification and PEGylation of pharmaceutical proteins mediated by transglutaminase

(2007) Angelo Fontana et al.   ADVANCED DRUG DELIVERY REVIEWS

The Biology of Interleukin-2

(2007) Thomas R. Malek   Annual Review of Immunology